Covid, from Ema the green light for the first preventive monoclonal

Green light from the European Medicines Agency Ema for the Evusheld * monoclonal antibody combination, developed by the Anglo-Swedish AstraZeneca for the prevention of Covid-19 in adults and adolescents from 12 years of age (weighing at least 40 kg). The drug is meant to be administered prior to potential exposure to the Sars-CoV-2 virus. The EU regulatory body gave the news of the positive verdict. EMA’s CHMP Committee for Medicinal Products for Human Use has today expressed a recommendation to grant marketing authorization for the mix of monoclonals tixagevimab and cilgavimab, designed to bind to the Spike protein of Sars-CoV-2 in two different sites. When they do, the virus cannot enter cells to multiply and is unable to cause infection. (continues)